Bortezomib does not reduce ABO-isoagglutinin titers and may not be useful for ABO-incompatible transplant desensitization.
Boothpur
Raghavender
R
Department of Medicine, Washington University School of Medicine, St Louis, Missouri, USA.
Torrence
Stephanie
S
Brennan
Daniel C
DC
D000017:ABO Blood-Group System / Q000276:immunology*; D000998:Antiviral Agents / Q000627:therapeutic use; D001787:Blood Group Incompatibility / Q000276:immunology*; D001897:Boronic Acids / Q000627:therapeutic use*; D000069286:Bortezomib; D003586:Cytomegalovirus Infections / Q000150:complications / Q000188:drug therapy; D004317:Doxorubicin / Q000627:therapeutic use; D015774:Ganciclovir / Q000031:analogs & derivatives / Q000627:therapeutic use; D006388:Hemagglutinins / Q000276:immunology*; D006801:Humans; D007676:Kidney Failure, Chronic / Q000601:surgery*; D016030:Kidney Transplantation / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy; D011480:Protease Inhibitors / Q000627:therapeutic use*; D011719:Pyrazines / Q000627:therapeutic use*; D000077562:Valganciclovir
D000017:ABO Blood-Group System; D000998:Antiviral Agents; D001897:Boronic Acids; D006388:Hemagglutinins; D011480:Protease Inhibitors; D011719:Pyrazines; D000069286:Bortezomib; D004317:Doxorubicin; D000077562:Valganciclovir; D015774:Ganciclovir